Top Midday Gainers

MT Newswires Live02-06

TransCode Therapeutics (RNAZ) reported Thursday the submission to the US Food and Drug Administration of an investigational new drug application amendment for a phase 2a trial with its lead therapeutic candidate, TTX-MC138. It is partnering with Quantum Leap Healthcare Collaborative.

Shares surged over 22% as intraday trading volume soared to over 11.3 million from a daily average of roughly 58,000.

Regal Rexnord (RRX) reported late Wednesday a year-over-year surge in Q4 revenue and adjusted earnings.

Shares jumped 13%, with intraday trading volume at over 3.1 million, compared with a daily average of about 806,000.

McKesson (MCK) late Wednesday reported fiscal Q3 adjusted net income and sales above market expectations, while revising up fiscal 2026 adjusted EPS guidance.

Shares jumped 18%, with intraday trading volume at over 1.46 million, compared with a daily average of about 705,000.

Price: 10.77, Change: +2.01, Percent Change: +22.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609586424?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 03:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609586424","market":"sh","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNAZ) reported Thursday the submission to the US Food and Drug Administration of an investigational new drug application amendment for a phase 2a trial with its lead therapeutic candidate, TTX-MC138. It is partnering with <a href=\"https://laohu8.com/S/QMCO\">Quantum</a> Leap Healthcare Collaborative.</p><p>Shares surged over 22% as intraday trading volume soared to over 11.3 million from a daily average of roughly 58,000.</p><p><a href=\"https://laohu8.com/S/RRX\">Regal Rexnord</a> (RRX) reported late Wednesday a year-over-year surge in Q4 revenue and adjusted earnings.</p><p>Shares jumped 13%, with intraday trading volume at over 3.1 million, compared with a daily average of about 806,000.</p><p>McKesson (MCK) late Wednesday reported fiscal Q3 adjusted net income and sales above market expectations, while revising up fiscal 2026 adjusted EPS guidance.</p><p>Shares jumped 18%, with intraday trading volume at over 1.46 million, compared with a daily average of about 705,000.</p><p>Price: 10.77, Change: +2.01, Percent Change: +22.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-06 03:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNAZ) reported Thursday the submission to the US Food and Drug Administration of an investigational new drug application amendment for a phase 2a trial with its lead therapeutic candidate, TTX-MC138. It is partnering with <a href=\"https://laohu8.com/S/QMCO\">Quantum</a> Leap Healthcare Collaborative.</p><p>Shares surged over 22% as intraday trading volume soared to over 11.3 million from a daily average of roughly 58,000.</p><p><a href=\"https://laohu8.com/S/RRX\">Regal Rexnord</a> (RRX) reported late Wednesday a year-over-year surge in Q4 revenue and adjusted earnings.</p><p>Shares jumped 13%, with intraday trading volume at over 3.1 million, compared with a daily average of about 806,000.</p><p>McKesson (MCK) late Wednesday reported fiscal Q3 adjusted net income and sales above market expectations, while revising up fiscal 2026 adjusted EPS guidance.</p><p>Shares jumped 18%, with intraday trading volume at over 1.46 million, compared with a daily average of about 705,000.</p><p>Price: 10.77, Change: +2.01, Percent Change: +22.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0868494617.USD","symbol_name":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2609586424","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609586424","pubTimestamp":1770319845,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransCode Therapeutics (RNAZ) reported Thursday the submission to the US Food and Drug Administration of an investigational new drug application amendment for a phase 2a trial with its lead therapeuti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","RRX":"Regal Rexnord","BK4175":"保健护理产品经销商","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0868494708.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) INC","LU0942090050.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD)  INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1983260115.SGD":"Janus Henderson Horizon Global Sustainable Equity A2 SGD-H","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4539":"次新股","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","LU0274383776.USD":"MANULIFE GF US SMALL CAP EQUITY \"AA\" (USD) INC","RNAZ":"TransCode Therapeutics  Inc.","BK4585":"ETF&股票定投概念","LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","MCK":"麦克森药物批发","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCK":1,"RRX":1,"RNAZ":1},"content_text":"TransCode Therapeutics (RNAZ) reported Thursday the submission to the US Food and Drug Administration of an investigational new drug application amendment for a phase 2a trial with its lead therapeutic candidate, TTX-MC138. It is partnering with Quantum Leap Healthcare Collaborative.Shares surged over 22% as intraday trading volume soared to over 11.3 million from a daily average of roughly 58,000.Regal Rexnord (RRX) reported late Wednesday a year-over-year surge in Q4 revenue and adjusted earnings.Shares jumped 13%, with intraday trading volume at over 3.1 million, compared with a daily average of about 806,000.McKesson (MCK) late Wednesday reported fiscal Q3 adjusted net income and sales above market expectations, while revising up fiscal 2026 adjusted EPS guidance.Shares jumped 18%, with intraday trading volume at over 1.46 million, compared with a daily average of about 705,000.Price: 10.77, Change: +2.01, Percent Change: +22.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609586424","isCrawlerRequest":true}